Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self-microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse-phase high-performance liquid chromatography (RP-HPLC) method for quantifying dasatinib in SMEDDS formulations. The RP-HPLC method utilized a mobile phase of methanol and 0.1% trifluoroacetic acid (55:45, v/v) and identified a peak wavelength for dasatinib at 324 nm. SMEDDS formulations comprised Capryol 90, Transcutol HP, and Tween 40. The method was validated according to ICH guidelines, demonstrating excellent linearity (R 2 = 0.9993), accuracy (recovery between 98% and 101%), and precision (relative standard deviation of 0.73%). It also showed stability and reliability with limits of detection and quantification of 0.17 and 0.50 µg/mL, respectively. This RP-HPLC method meets all validation criteria and provides a robust, cost-effective tool for analyzing dasatinib in SMEDDS formulations.
Brain tumors during pregnancy are rare and pose unique challenges in diagnosis, management, and anesthetic care. This report is novel owing to the rare coexistence of a giant anaplastic oligodendroglioma with an ongoing pregnancy requiring urgent dual surgical interventions. A 27-year-old, right‐handed, Middle Eastern Saudi woman at 35 weeks of gestation presented with neurological symptoms, including partial loss of consciousness, left-sided ptosis, and severe headaches. Imaging revealed a large left temporoparietal mass with significant midline shift, diagnosed as an anaplastic oligodendroglioma. She underwent an emergency cesarean section and craniotomy under general anesthesia. Postoperative recovery was uneventful for both the mother and the newborn. This case highlights the critical importance of multidisciplinary coordination, individualized anesthetic planning, and timely surgical decision-making in managing complex neurosurgical cases during pregnancy. The combined obstetric–neurosurgical approach contributed to a favorable maternal and neonatal outcome.
Foot drop (FD) refers to a clinical picture characterized by the inability to lift the foot against gravity due to weakness of the dorsiflexor muscles. Patients with FD typically present with an abnormal gait marked by exaggerated flexion of the knee and hip joints, along with internal rotation of the foot, which may increase the risk of falls and injuries. Intraneural ganglion cysts are benign, fluid-filled lesions located within the epineurium of peripheral nerves. We report the case of a 22-year-old male who presented with right lower limb pain and numbness and later developed acute weakness of the right foot, resulting in complete FD that persisted for four months. He denied any history of trauma and was otherwise medically healthy. On examination, there was muscle wasting in the anterior and lateral compartments of the right leg, complete FD with 0/5 power in dorsiflexion and eversion, and reduced sensation along the distribution of the right common peroneal nerve (CPN). Local examination revealed a palpable and tender swelling around the neck of the right fibula. Plain X-rays revealed no abnormalities; however, MRI demonstrated a small cystic soft tissue lesion located posterolateral to the proximal fibular head, measuring 5 x 1.5 x 2.5 cm. Surgical exploration of the right CPN was performed with neurolysis and excision of the lesion. Histopathological examination confirmed the diagnosis of a ganglion cyst. Postoperatively, the patient had an uneventful recovery, and after two weeks of physical and occupational therapy, he reported improvement in pain and numbness, although motor function remained unchanged at that time. The association between FD and ganglion cysts is a rare pathology; however, it should be included in the differential diagnosis of FD, particularly in the absence of trauma.
Background The extravascular implantable cardioverter-defibrillator (EV ICD) is a commercially available device for patients at risk of sudden cardiac death. Results from pre-market studies have demonstrated a low complication rate and effective therapy through chronic follow-up. Lead placement outside the vasculature has the potential to reduce the severity of infections compared to other ICD options. Objective To report on details of infection occurrence and management from the EV ICD Pivotal study. Methods The EV ICD Pivotal study was an international, prospective, single-arm, premarket clinical study. Patients with any system- or procedure-related infection noted were included in our analysis. Results In the EV ICD Pivotal study, 316 patients had an implant attempt, of which 15 had a system- or procedure-related infection (4.7%, 9-737 days post-implant) through an average 29.0±10.6 months follow-up. Of these infections, eight (2.5% of Pivotal patients) were classified as major complications, three as minor, and four as observations. Most (n=9, 60%) infections were addressed through medication with or without wound care while 6 (40%) resulted in system removal. The infectious organism was reported for six. There were no reports of mediastinitis, sepsis, or endocarditis. Conclusions The results from this study support that EV ICD-related infections are treatable with antibiotic therapy or system removal and major infections are rare. Importantly, no system- or procedure-related systemic infections such as mediastinitis, sepsis, or endocarditis were reported.
